Selective vascular endothelial growth factor receptor inhibitors provide limited benefits for metastatic colorectal cancer: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Current pharmaceutical design"
DOI: 10.2174/1381612826666200218095932
Abstract: BACKGROUND Metastatic colorectal cancer (mCRC) is one of the most common and deadly cancers worldwide. For most patients diagnosed with mCRC and managed with 5-fluorouracil (5-FU)/leucovorin plus oxaliplatin (FOLFOX), the median survival time is still… read more here.
Keywords: folfox4; vegfr inhibitors; selective vegfr; rate ... See more keywords